RT Journal Article
T1 Gene Silencing of SOCS3 by siRNA Intranasal Delivery Inhibits Asthma Phenotype in Mice
A1 Zafra MP, 
A1 Mazzeo C, 
A1 Gámez C, 
A1 Rodriguez Marco A, 
A1 de Zulueta A, 
A1 Sanz V., 
A1 Bilbao I, 
A1 Ruiz-Cabello J, 
A1 Zubeldia Ortuño, José Manuel
A1 del Pozo V, 
AB Suppresors of cytokine signaling (SOCS) proteins regulate cytokine responses and control immune balance. Several studies have confirmed that SOCS3 is increased in asthmatic patients, and SOCS3 expression is correlated with disease severity. The objective of this study was to evaluate if delivering of SOCS3 short interfering RNA (siRNA) intranasally in lungs could be a good therapeutic approach in an asthma chronic mouse model. Our results showed that intranasal treatment with SOCS3-siRNA led to an improvement in the eosinophil count and the normalization of hyperresponsiveness to methacholine. Concomitantly, this treatment resulted in an improvement in mucus secretion, a reduction in lung collagen, which are prominent features of airway remodeling. The mechanism implies JAK/STAT and RhoA/Rho-kinase signaling pathway, because we found a decreasing in STAT3 phosphorylation status and down regulation of RhoA/Rho-kinase protein expression. These results might lead to a new therapy for the treatment of chronic asthma.
PB www.plosone.org
SN 1932-6203
YR 2014
FD 2014-03-17
LK https://hdl.handle.net/20.500.14352/115735
UL https://hdl.handle.net/20.500.14352/115735
LA eng
NO Zafra MP, Mazzeo C, Gámez C, Rodriguez Marco A, de Zulueta A, Sanz V, Bilbao I, Ruiz-Cabello J, Zubeldia JM, del Pozo V. Gene silencing of SOCS3 by siRNA intranasal delivery inhibits asthma phenotype in mice. PLoS One. 2014 Mar 17;9(3):e91996. doi: 10.1371/journal.pone.0091996. Erratum in: PLoS One. 2014;9(8):e105924. PMID: 24637581; PMCID: PMC3956882.
DS Docta Complutense
RD 16 abr 2025